NPI 1164976908: Open Payments
NPI 1164976908. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$83 in 3 payments from 3 companies in 2025. Trend: 2023 $869 · 2024 $1,225 · 2025 $83
Food & beverage: $63Education: $20
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $49 |
| Aveo Pharmaceuticals, Inc. | 1 | $20 |
| Gilead Sciences, Inc. | 1 | $14 |
Products named: FRUZAQLA, FOTIVDA, Trodelvy.
